======= CSRP2BP =======
== Gene Information ==
* **Official Symbol**: KAT14
* **Official Name**: lysine acetyltransferase 14
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=57325|57325]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9H8E8|Q9H8E8]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=CSRP2BP&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CSRP2BP|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/617501|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. May function as a scaffold for the ATAC complex to promote ATAC complex stability. Has also weak histone acetyltransferase activity toward histone H4. Required for the normal progression through G1 and G2/M phases of the cell cycle. {ECO:0000269|PubMed:19103755}.
|Acetyltransf 1|
|LIM domain binding|
|Ada2/Gcn5/Ada3 transcription activator complex|
|histone H3 acetylation|
|histone acetyltransferase activity|
|histone acetylation|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|G2/M transition of mitotic cell cycle|
|cell cycle G2/M phase transition|
|protein acetylation|
|protein acylation|
|mitotic cell cycle phase transition|
|cell cycle phase transition|
|peptidyl-lysine modification|
|histone modification|
|covalent chromatin modification|
|mitotic cell cycle process|
|mitotic cell cycle|
|chromatin organization|
|peptidyl-amino acid modification|
|cell cycle process|
|chromosome organization|
|cell cycle|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp390|Pifithrin-alpha 20μM R07 exp390]]|-2.05|
|[[:results:exp281|Disulfiram 4.3μM R06 exp281]]|-1.94|
|[[:results:exp42|BI-6727 0.001μM R01 exp42]]|-1.74|
|[[:results:exp243|S-trityl-L-cysteine 0.5μM R05 exp243]]|-1.73|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|1.79|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|1.82|
|[[:results:exp134|MS023 2μM R03 exp134]]|1.97|
|[[:results:exp135|MS023 7μM R03 exp135]]|2.69|
^Gene^Correlation^
|[[:human genes:z:zzz3|ZZZ3]]|0.475|
|[[:human genes:m:mbip|MBIP]]|0.461|
|[[:human genes:t:tada2a|TADA2A]]|0.413|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 2973
* **Expression level (log2 read counts)**: 5.23
{{:chemogenomics:nalm6 dist.png?nolink |}}